Layoffs are looming in Switzerland as Novartis announces its plans to cut upwards of 550 full-time positions by the end of ...

AI and computational modeling are reducing reliance on animal testing by simulating human biology, improving drug safety and ...

Businesses want to be available to provide for employees and be competitive. They want workers to be able to go to the HR ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship ...

Amid the usual hustle before a big medical conference or industry trade show, editors are often buried under a flood of news ...

Psychedelics have demonstrated significant progress, generating enthusiasm across the neuroscience industry and leading to ...

Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about ...

Following the company’s announcement of lackluster results from both its Phase III trials, Novo’s shares dropped nearly 9% pre-market, a significant shift the company hasn’t seen in its shares since ...

Cancerguard, a multi-cancer early detection blood test.

Regeneron announced the FDA’s approval of two indications of Eylea HD, including an 8mg injection for patients with macular ...

Each step in the patient journey, benefit verification, prior authorization, fulfillment, and adherence, creates a potential failure point when systems don’t communicate. In many first-generation ...